Equities research analysts forecast that Puma Biotechnology Inc (NASDAQ:PBYI) will post earnings per share (EPS) of ($2.02) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Puma Biotechnology’s earnings, with estimates ranging from ($2.07) to ($1.97). Puma Biotechnology posted earnings per share of ($1.22) in the same quarter last year, which would suggest a negative year over year growth rate of 65.6%. The company is expected to report its next earnings results on Wednesday, March 7th.

According to Zacks, analysts expect that Puma Biotechnology will report full year earnings of ($8.17) per share for the current fiscal year, with EPS estimates ranging from ($8.22) to ($8.11). For the next year, analysts anticipate that the business will post earnings of ($5.63) per share, with EPS estimates ranging from ($5.85) to ($5.37). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Puma Biotechnology.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million during the quarter, compared to analyst estimates of $3.78 million. During the same quarter in the previous year, the company posted ($1.11) earnings per share.

Several equities analysts recently commented on the company. Royal Bank of Canada dropped their target price on Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating for the company in a research note on Friday, November 10th. They noted that the move was a valuation call. Citigroup reiterated a “buy” rating and issued a $156.00 target price (up from $114.00) on shares of Puma Biotechnology in a research note on Thursday, October 5th. Leerink Swann upped their target price on Puma Biotechnology to $140.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Bank of America reiterated a “buy” rating and issued a $135.00 target price (up from $117.00) on shares of Puma Biotechnology in a research note on Monday, October 9th. Finally, BidaskClub upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $130.67.

In other Puma Biotechnology news, insider Charles R. Eyler sold 1,322 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $105.46, for a total transaction of $139,418.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 21.10% of the company’s stock.

A number of large investors have recently made changes to their positions in PBYI. Cubist Systematic Strategies LLC acquired a new stake in Puma Biotechnology during the second quarter worth about $146,000. Kazazian Asset Management LLC acquired a new stake in shares of Puma Biotechnology in the second quarter valued at about $209,000. Ameritas Investment Partners Inc. grew its stake in shares of Puma Biotechnology by 5.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 140 shares in the last quarter. ProShare Advisors LLC acquired a new stake in shares of Puma Biotechnology in the second quarter valued at about $222,000. Finally, Stifel Financial Corp acquired a new stake in shares of Puma Biotechnology in the second quarter valued at about $240,000. Institutional investors own 96.00% of the company’s stock.

Puma Biotechnology (NASDAQ:PBYI) opened at $99.25 on Friday. The company has a market capitalization of $3,591.58, a price-to-earnings ratio of -12.13 and a beta of 0.72. Puma Biotechnology has a 12 month low of $28.35 and a 12 month high of $136.90.

ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/14/2-02-eps-expected-for-puma-biotechnology-inc-pbyi-this-quarter.html.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.